Page last updated: 2024-12-04

chlordiazepoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2712
CHEMBL ID451
CHEBI ID3611
CHEBI ID94781
SCHEMBL ID145243
SCHEMBL ID18474
MeSH IDM0004133

Synonyms (134)

Synonym
radepur
AC-13012
HMS3394C19
3h-1,4-benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide
3h-1,4-benzodiazepin-2-amine, 7-chloro-n-methyl-5-phenyl-, 4-oxide
KBIO1_000995
DIVK1C_000995
7-chloro-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-amine 4-oxide
kalmocaps
ifibrium
7-chloro-2-(methylamino)-5-phenyl-3h-1,4-benzodiazepine 4-oxide
viopsicol
7-cloro-2-metilamino-5-fenil-3h-1,4-benzodiazepina 4-ossido [italian]
napoton
psicosan
librinin
mesural
decacil
balance (pharmaceutical)
librelease
chlozepid
mildmen
sonimen
zetran
hsdb 3028
disarim
zeisin
einecs 200-371-0
chlordiazepoxydum
chlorodiazepoxide
chlordiazepoxidum [inn-latin]
chloridiazepide
7-chlor-2-methylamino-5-phenyl-3h-1,4-benzodiazepin-4-oxid [german]
eden-psich
clordiazepoxido [inn-spanish]
lygen
clordiazepossido [italian]
control
menrium
chlordiazepoxide
SPECTRUM5_001623
IDI1_000995
58-25-3
librium
MLS001424220
7-chloro-2-methylamino-5-phenyl-3h-1,4-benzodiazepin-4-oxide
methaminodiazepoxide
DB00475
clopoxide
chloradiazepoxide
D00267
chlordiazepoxide (jp17/usp/inn)
3h-1,4-benzodiazepin-2-amine,7-chloro-n-methyl-5-phenyl-,4-oxide
libritabs (tn)
KBIOGR_001016
NINDS_000995
SPECTRUM2_001157
SPECTRUM4_000578
SPBIO_001113
chlordiazepoxidum
silibrin
helogaphen
elenium
CHEBI:3611 ,
tropium
risolid
libritabs
MLS001066622
smr000469226
HMS2052C19
7-chloro-2-methylamino-5-phenyl-3h-1,4-benzodiazepine-4-oxide
CHEMBL451 ,
chlordiazepoxide civ
HMS503G11
bdbm50007664
7-chloro-4-hydroxy-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-imine
NCGC00246347-01
tox21_111568
dtxsid4046022 ,
dtxcid2026022
tox21_111567
cas-58-25-3
BBL010791
chlordiazepoxid
STK597142
HMS2231M10
AKOS015963131
CCG-101136
AKOS005518509
MLS003899195
clordiazepossido
7-chlor-2-methylamino-5-phenyl-3h-1,4-benzodiazepin-4-oxid
7-cloro-2-metilamino-5-fenil-3h-1,4-benzodiazepina 4-ossido
unii-6rz6xez3cr
chlordiazepoxide [usp:inn:ban:jan]
6rz6xez3cr ,
clordiazepoxido
AB06298
limbitrol component chlordiazepoxide
menrium component chlordiazepoxide
limbitrol ds component chlordiazepoxide
chlordiazepoxide civ [usp-rs]
chlordiazepoxide component of limbitrol ds
chlordiazepoxide component of limbitrol
chlordiazepoxide component of menrium
chlordiazepoxide [ep monograph]
chlordiazepoxide [mi]
chlordiazepoxide [inn]
chlordiazepoxide [usp monograph]
chlordiazepoxide [vandf]
chlordiazepoxide [jan]
chlordiazepoxide [mart.]
chlordiazepoxide [hsdb]
chlordiazepoxide [who-dd]
chlordiazepoxide [orange book]
HMS3373M10
gtpl3370
ANTSCNMPPGJYLG-UHFFFAOYSA-N
AB00053219-06
SCHEMBL145243
NC00386
SCHEMBL18474
W-105404
CHEBI:94781
chlordiazepoxide 1.0 mg/ml in methanol
chlordiazep-oxide hcl
chlordiazepoxide-hcl
7-chloro-2-(methylamino)-5-phenyl-3h-1,4-benzodiazepin-4-ium-4-olate
VS-02683
(1e,4e)-7-chloro-2-(methylamino)-5-phenyl-3h-benzo[e][1,4]diazepine 4-oxide
Q178566
7-chloro-2-(methylimino)-5-phenyl-2,3-dihydro-4h-1,4-benzodiazepin-4-ol
DTXSID40861935
chlordiazepoxide, 1mg/ml in acetonitrile

Research Excerpts

Overview

Chlordiazepoxide is a sedative-hypnotic drug widely employed as a transquilizer and anti-depressant. It is a benzodiazepine that is widely used as a minor tranquilizer.

ExcerptReferenceRelevance
"Chlordiazepoxide is a sedative-hypnotic drug widely employed as a transquilizer and anti-depressant. "( Voltammetric behavior and quantification of the sedative-hypnotic drug chlordiazepoxide in bulk form, pharmaceutical formulation and human serum at a mercury electrode.
El-Hallag, IS; El-Hefnawey, GB; Ghoneim, EM; Ghoneim, MM, 2004
)
2
"Chlordiazepoxide is a benzodiazepine that is widely used as a minor tranquilizer. "( Chlordiazepoxide block of two types of calcium channels in neuroblastoma cells.
Narahashi, T; Reuveny, E; Twombly, DA, 1993
)
3.17

Effects

Chlordiazepoxide has a dual effect: it enhances the action of GABA at GABAA receptors and depresses K+ -evoked release of [3H]noradrenaline in the absence of GABA. It is resistant, except at high doses, to the opiate antagonist naloxone.

ExcerptReferenceRelevance
"Chlordiazepoxide has a dual effect: it enhances the action of GABA at GABAA receptors and depresses K+ -evoked release of [3H]noradrenaline in the absence of GABA."( The role of pre-synaptic GABA and benzodiazepine receptors in the control of noradrenaline release in rat hippocampus.
Fillenz, M; Fung, SC, 1983
)
0.99
"Chlordiazepoxide has a dual effect: it enhances the action of GABA at GABAA receptors and depresses K+ -evoked release of [3H]noradrenaline in the absence of GABA."( The role of pre-synaptic GABA and benzodiazepine receptors in the control of noradrenaline release in rat hippocampus.
Fillenz, M; Fung, SC, 1983
)
0.99
"Chlordiazepoxide (CDP) has been previously shown to possess antinociceptive properties that are resistant, except at high doses, to the opiate antagonist naloxone. "( Chlordiazepoxide antinociception: cross-tolerance with opiates and with stress.
Bodnar, RJ; Brutus, M; Glusman, M; Kelly, DD; Mansour, A; Thomas, LW, 1980
)
3.15
"Chlordiazepoxide which, it has been argued, produces behavioural changes similar to those observed after hippocampal lesions was found to disrupt performance at doses greater than 4 mg/kg (i.m.)."( The effects of chlordiazepoxide on a delayed pair comparison task in pigeons.
Iversen, SD; Sahgal, A, 1978
)
1.33
"Chlordiazepoxide has been reported antagonize TRH binding and TRH-induced phospholipid breakdown."( Pituitary thyrotropin-releasing hormone (TRH) receptors: effects of TRH, drugs mimicking TRH action, and chlordiazepoxide.
Hinkle, PM; Shanshala, ED, 1989
)
1.21
"Chlordiazepoxide has been shown to increase significantly social interaction between pairs of male rats and this increase can be reversed by RO 15-1788, 20 mg kg-1 i.p."( Central effects of nicotinamide and inosine which are not mediated through benzodiazepine receptors.
Bold, JM; Gardner, CR; Walker, RJ, 1985
)
0.99
"Chlordiazepoxide (CDE) has been shown to antagonize the effects of TRH to stimulate the hydrolysis of phosphoinositides and elevate cytoplasmic free calcium in rat pituitary tumor (GH3) cells. "( Evidence for tight coupling of receptor occupancy by thyrotropin-releasing hormone to phospholipase C-mediated phosphoinositide hydrolysis in rat pituitary cells: use of chlordiazepoxide as a competitive antagonist.
Gershengorn, MC; Paul, ME, 1986
)
1.91

Actions

Chlordiazepoxide led to an increase in ethanol mix responding at 2 mg/kg. No dose affected sucrose responding. Chlordiazepoxy seemed to disinhibit the ferrets when they were presented with large rats.

ExcerptReferenceRelevance
"Chlordiazepoxide led to an increase in ethanol mix responding at 2 mg/kg and a decrease in ethanol mix responding at higher doses; no dose affected sucrose responding."( Ro 15-4513 selectively attenuates ethanol, but not sucrose, reinforced responding in a concurrent access procedure; comparison to other drugs.
Petry, NM, 1995
)
1.01
"Chlordiazepoxide seemed to disinhibit the ferrets when they were presented with large rats, which they normally attack more cautiously."( Instinctive predatory behavior of the ferret (Putorius putorius furo L.) modified by chlordiazepoxide hydrochloride (Librium).
Apfelbach, R, 1978
)
1.2
"Chlordiazepoxide increased the lower rates of lever pressing maintained under the fixed interval schedule but generally decreased the higher response rates under the fixed ratio schedule."( Effect of chlordiazepoxide on schedule-controlled responding and schedule-induced drinking.
Bacotti, AV; Barrett, JE, 1976
)
1.38
"Chlordiazepoxide did not inhibit the small bombesin-induced rise in [3H]-InslP."( Chlordiazepoxide is a competitive thyrotropin-releasing hormone receptor antagonist in GH3 pituitary tumour cells.
Drummond, AH, 1985
)
2.43

Treatment

Chlordiazepoxide pretreatment decreased basal levels of plasma arginine-vasopressin (AVP) and attenuated picrotoxin-induced increases in plasma AVP and blood pressure compared to saline-pretreated spinal animals. Pretreatment enhanced the stimulatory effect of the chlordiazep oxycodone-amphetamine combination.

ExcerptReferenceRelevance
"The chlordiazepoxide treatment produced suppression of rapid eye movement (REM) sleep lasting for about 4 days and virtually eliminated delta sleep (stages III and IV) during the recovery period."( Residual effects of ethanol and chlordiazepoxide treatments for alcohol withdrawal.
Allen, RP; Funderburk, FR; Wagman, AM, 1978
)
1.02
"Chlordiazepoxide pretreatment decreased basal levels of plasma arginine-vasopressin (AVP) and attenuated picrotoxin-induced increases in plasma AVP and blood pressure compared to saline-pretreated spinal animals. "( Benzodiazepine receptors modulate circulating plasma vasopressin concentration.
DiMicco, JA; Wible, JH; Zerbe, RL, 1985
)
1.71
"Chlordiazepoxide pretreatment enhanced the stimulatory effect of the chlordiazepoxide-amphetamine combination."( Facilitation of stimulatory effect of chlordiazepoxide-amphetamine combination by subacute administration of chlordiazepoxide in mice.
Renzi, P; Sansone, M; Vetulani, J, 1986
)
1.26
"Chlordiazepoxide-treated patients generally did significantly better on sleep difficulty but significantly worse on anger-hostility and interpersonal sensitivity than did imipramine- or placebo-treated patients."( Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients.
Covi, L; Downing, R; Faden, V; Kahn, RJ; Lasseter, VK; Lipman, RS; McNair, DM; Rickels, K, 1986
)
1.35
"Pretreatment with chlordiazepoxide reversed these changes."( Effect of acute and chronic stress on leucocyte count: modulation by chlordiazepoxide.
Koner, BC; Suresh, PS, 2012
)
0.94
"Pretreatment with chlordiazepoxide prevented the stress-induced increases in unit-activity, whereas, suppressed units were not affected by the drug treatment."( The anterior cingulate cortex and stress: effects of chlordiazepoxide on unit-activity and stimulation-induced gastric pathology in rats.
Henke, PG, 1984
)
0.84

Toxicity

The LD50 of diazepam and chlordiazepoxide were not modified by physostigmine administration, but that of flurazepam was significantly decreased. In the first experiment, 87% of chlordsiazepoxide-treated animals survived a lethal dose of toxic ryegrass.

ExcerptReferenceRelevance
" In the first experiment, 87% of chlordiazepoxide-treated animals survived a lethal dose of toxic ryegrass."( Treatment of ovine annual ryegrass toxicity with chlordiazepoxide.
Petterson, DS; Purcell, DA; Richards, IS, 1979
)
0.8
" The LD50 of diazepam and chlordiazepoxide were not modified by physostigmine administration, but that of flurazepam was significantly decreased."( Effects of physostigmine on benzodiazepine toxicity.
Bamonte, F; Ongini, E; Parravicini, L, 1981
)
0.56
" Clinical efficacy was assessed by Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWA-Ar) and tolerability by the nature and severity of adverse events."( A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016
)
0.65
" Both the drugs showed good tolerability with mild self-limiting adverse events."( A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016
)
0.65

Pharmacokinetics

The elimination half-life of chlordiazepoxide and diazepam increases with age. This may cause prolongation of action after a single dose and delayed accumulation on multiple dosing in elderly patients.

ExcerptReferenceRelevance
" These findings and other results of pharmacokinetic research have clinical implications in terms of dosage schedules, drug accumulation during long-term therapy, antianxiety therapy in the elderly, drug interactions, pharmacotherapy in specific disease states, and the influence of route of administration on drug action."( Clinical implications of benzodiazepine pharmacokinetics.
Greenblatt, DJ; Shader, RI, 1977
)
0.26
"Three healthy volunteers (2 male and one female) participated in single- and multiple-dose pharmacokinetic studies of oral chlordiazepoxide (CDX) hydrochloride."( Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses.
Franke, K; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1978
)
0.79
"The elimination half-life of chlordiazepoxide and diazepam increases with age, and this may cause prolongation of action after a single dose and delayed accumulation on multiple dosing in elderly patients."( [Pharmacokinetic of benzodiazepines in old age].
Vozeh, S, 1981
)
0.55
"Knowledge of the pharmacokinetic properties of the benzodiazepines is playing an increasingly important role in their use during pregnancy, labour and lactation."( Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.
Kanto, JH, 1982
)
0.26
" Application of the methods to pharmacokinetic studies in the rat found the elimination half-life of Ro 15-1788 from rat brain to be 16 min."( Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat.
Abernethy, DR; File, SE; Greenblatt, DJ; Lister, RG, 1984
)
0.27
" Therefore, in order to investigate the distributive profile for MB as compared with that for CDP, pharmacokinetic parameters for MB and CDP were estimated from plasma concentration--time data following simultaneous intravenous administration by a bolus injection and by a contrast rate infusion in rabbits."( Dose dependency of apparent volumes of distribution for methylene blue in rabbits.
Kozaki, A; Watanabe, J, 1981
)
0.26
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Chlordiazepoxide's effects on feeding parameters were generally additive with those of either d-amphetamine or fenfluramine. The sedative effects of the two drugs were never additive. When the phenylquinolines were combined with chlordiazepoxy the degree of sedation was equal to that seen with either drug given alone.

ExcerptReferenceRelevance
" Also alcohol alone, and all the drugs in combination with alcohol retarded learning acquisition."( Effects on learning and memory of 2-week treatments with chlordiazepoxide lactam, N-desmethyldiazepam, oxazepam and methyloxazepam, alone or in combination with alcohol.
Liljequist, R; Linnoila, M; Palva, E, 1979
)
0.5
" The effects of chlordiazepoxide on feeding parameters were generally additive with those of either d-amphetamine or fenfluramine, whenever chlordiazepoxide was given in combination with one of the anorectic drugs."( Feeding parameters with two food textures after chlordiazepoxide administration, alone or in combination with d-amphetamine or fenfluramine.
Cooper, SJ; Francis, RL, 1979
)
0.86
" Additionally, d-amphetamine or naloxone was administered with Gbl to test hypotheses of Gbl's neurochemical mechanisms of action."( Gamma-butyrolactone's discriminability and effect on low rates of lever pressing by rats: alone and in combination with D-amphetamine and naloxone.
Cleary, J; McIntire, KD; Weinfurter, S, 1988
)
0.27
" Brief information on the following reports of drug-drug interactions is given in this article with the intention of giving these reports wider publicity and, possibly, encouraging further observation and research to establish or disprove their validity in a larger and wider range of patients or volunteer subjects."( Early reports on drug interactions.
D'Arcy, PF, 1983
)
0.27
" 3 When the phenylquinolines were combined with chlordiazepoxide the degree of sedation was equal to that seen with either drug given alone, whichever produced the greater sedation; the sedative effects of the two drugs were never additive."( Sedative effects of PK 9084 and PK 8165, alone and in combination with chlordiazepoxide.
File, SE, 1983
)
0.75
"3-10 mg/kg) alone and in combination with flumazenil (0."( Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.
Nader, MA; Woolverton, WL, 1995
)
0.29
" In this study, we sought to further examine this mechanism using a novel drug-drug conditioning procedure."( An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm.
He, W; Li, M; Mead, A, 2009
)
0.35

Bioavailability

absolute bioavailability of oral chlordiazepoxide was not less than 100% and was unrelated to age or sex. Coadministration of CDX with Maalox did not change the completeness ofCDX absorption but significantly slowed its rate of absorption.

ExcerptReferenceRelevance
" Coadministration of CDX with Maalox did not change the completeness of CDX absorption but significantly slowed its rate of absorption and the rate of desmethylchlordiazepoxide (DMCDX) appearance."( Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.
Franke, K; Greenblatt, DJ; Harmatz, JS; Koch-Weser, J; Shader, RI, 1977
)
0.69
"The period of time after administration over which blood level measurements are required to obtain a reliable bioavailability comparison of two or more formulations of the same drug was considered by the analysis of bioavailability data taken from the literature."( Comparative bioavailabilities from truncated blood level curves.
Lovering, EG; McGilveray, IJ; McMillan, I; Tostowaryk, W, 1975
)
0.25
" Absolute bioavailability of oral chlordiazepoxide was not less than 100%, and was unrelated to age or sex."( Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition.
Abernethy, DR; Divoll, MK; Greenblatt, DJ; Harmatz, JS; Ochs, HR; Shader, RI, 1989
)
0.86
" Pharmacokinetics and bioavailability are certainly altered by such modifications, usually in a positive sense."( Peptide derivatives as prodrugs.
Thomas, WA, 1986
)
0.27
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"A series of high-affinity GABA(A) agonists with good oral bioavailability in rat and dog and functional selectivity for the GABA(A)alpha2 and -alpha3 subtypes is reported."( Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
Atack, JR; Blackaby, WP; Brown, N; Castro, JL; Cook, SM; Crawforth, JM; Ferris, P; Goodacre, SC; Hallett, DJ; Kelly, S; Lewis, RT; Marshall, G; Owens, AP; Pike, A; Smith, AJ; Sohal, B; Stanley, J; Street, LJ; Wafford, KA, 2006
)
0.33
" The MCH1 receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively)."( Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists Part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit.
Andersen, K; Chen, CA; Craig, DA; Daniewska, I; De Leon, J; Forray, C; Hegde, LG; Jiang, Y; Kong, R; Li, B; Lu, K; Marzabadi, MR; Wetzel, JM; Wolinsky, TD, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" We used a novel, potent, and selective orally bioavailable antagonist, LY2940094, to test the hypothesis that blockade of NOP receptors would induce antidepressant effects."( A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Barth, V; Browning, M; Dawson, GR; Harmer, CJ; Jackson, K; Kakar, R; Krikke-Workel, J; McCarthy, A; Mohs, R; Post, A; Smart, TS; Statnick, M; Wafford, K; Witkin, JM, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Chlorpromazine caused a slight shift in the dose-response curves as did chlordiazepoxide when used with phencyclidine. Twenty anxious patients were treated with medazepam, diazepam, Chlo, amylobarbitone and placebo, each given in flexible dosage for 2-4 weeks.

ExcerptRelevanceReference
" The dose-response curve for diazepam asymptoted over the range 15 to 100 mg/kg, ip whereas dose-response curves for flurazepam and chloridazepoxide were more linear."( Discriminable effects of benzodiazepines.
Overton, DA, 1976
)
0.26
" Twenty anxious patients were treated with medazepam, diazepam, chlordiazepoxide, amylobarbitone and placebo, each given in flexible dosage for 2-4 weeks."( Plasma concentrations of benzodiazepines.
Bond, AJ; Hailey, DM; Lader, MH, 1977
)
0.5
" These findings and other results of pharmacokinetic research have clinical implications in terms of dosage schedules, drug accumulation during long-term therapy, antianxiety therapy in the elderly, drug interactions, pharmacotherapy in specific disease states, and the influence of route of administration on drug action."( Clinical implications of benzodiazepine pharmacokinetics.
Greenblatt, DJ; Shader, RI, 1977
)
0.26
" New dose-response curves obtained following this treatment indicated that tolerance did not develop to the antagonism of the PTZ discriminative stimulus by these benzodiazepines."( Lack of tolerance development to benzodiazepines in antagonism of the pentylenetetrazol discriminative stimulus.
Lal, H; Miksic, S; Shearman, GT, 1979
)
0.26
"3 PB, tested at concentrations up to 80 muM, produced variable effects on the dose-response curve to GABA."( Reversal of the action of amino acid antagonists by barbiturates and other hypnotic drugs.
Bowery, NG; Dray, A, 1978
)
0.26
" The inability of several anxiolytic compounds to show activity at high doses prompted an investigation of the effect on corticosteroid levels of these drugs over a wider dosage range."( The effect of various doses of minor tranquilizers on plasma corticosteroids in stressed rats.
Barsuhn, C; Lahti, RA, 1975
)
0.25
" Furthermore, the combination dosing proved nearly three times more potent than the potency that was predicted from simple additivity of the individual drug effects."( A benzodiazepine-anticholinergic drug synergism in the prevention of stress-induced gastric mucosal erosion in mice.
Baker, T; Riker, WF; Zeldes, G,
)
0.13
" Bases for selection include: (1) availability of other than oral dosage forms; (2) differences in additive effect with alcohol in producing central nervous system depression; (3) differences in anticonvulsant effect; and (4) differences in duration of effect in the body (ie, half-life)."( Selection among benzodiazepines for alcohol withdrawal.
Keeler, MH; Miller, WC, 1977
)
0.26
" Dose-response related decrements in male sexual behavior were observed following chlorpromazine and chlordiazepoxide."( Effects of chlordiazepoxide, oxazepam, chlorpromazine, and d-amphetamine on sexual responses in male and female hamsters.
Carter, CS; Daily, RF; Leaf, R, 1977
)
0.86
" With increase of antidepressants dosage received by a subordinate rat its competing ability becomes enhanced too; this may cause a change in domination."( [Effect of pharmacologic substances on the dominance-submission relationship in a pair of rats].
Kampov-Polevoi, AB, 1978
)
0.26
" Thus certain subjective effects of antianxiety agents after oral dosage may depend on the rate of drug absorption and may be attenuated or eliminated if the absorption rate is reduced."( Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.
Franke, K; Greenblatt, DJ; Harmatz, JS; Koch-Weser, J; Shader, RI, 1977
)
0.49
" The sensitivity limit for diazepam and nordiazepam, its major metabolite, renders the assay useful only for the determination of plasma concentrations resulting from high dosage of diazepam."( Determination of chlordiazepoxide, diazepam, and their major metabolites in blood or plasma by spectrophotodensitometry.
Bratin, K; Brooks, MA; de Silva, JA; Stronjny, N, 1977
)
0.6
" Dosage of each drug used in this experiment was calculated by determining the dosage which caused the same degree of muscle relaxation and sedative action in mice (see, Fig."( [Conditioning of emotional behavior originating at the hypothalamus. (2) Effects of drugs on conflict-induced behavior models].
Abe, Y; Mineo, K; Yanaura, S, 1976
)
0.26
" The beginning dosage of medication should be lower than for younger patients, and elderly patients must be monitored carefully for side effects."( Depression in elderly patients.
Fann, WE; Wheless, JC, 1975
)
0.25
" The rats (drug dependence-experimented rats) who survived the first stage of this experiment were continuously subjected to re-administration by the same dosage schedule as in Exp."( [Comparison of development of drug dependence in naive and drug dependence-experienced rats].
Tagashira, E; Yanaura, S, 1975
)
0.25
" At appropriate doses the CDP effect is reversed by repeated testing, by pretreatment with CDP, and by concomitant dosing with caffeine."( The mechanism of anti-muricidal effects of chlordiazepoxide.
Feldman, RS; Quenzer, LF,
)
0.39
" Dose-response curves were determined and generalization tests were performed for different benzodiazepine and nonbenzodiazepine anxiolytics."( Assessment of the stimulus properties of anxiolytic drugs by means of the conditioned taste aversion procedure.
Hijzen, TH; Olivier, B; Slangen, JL; Van Hest, A, 1992
)
0.28
" Using a cumulative dosing procedure, PTZ substituted for PTZ, and MDZ, chlordiazepoxide and diazepam (DZP) substituted for MDZ, in a dose-dependent manner."( Tolerance, cross-tolerance and withdrawal in rats made dependent on diazepam.
Boone, MS; Emmett-Oglesby, MW; Pugh, SL, 1992
)
0.52
" Spectral analysis of the EEG did not distinguish between the multi and single dosage schedules regarding the respective drugs in the low doses administered."( The comparison of the effects of multi and single doses of buspirone, chlordiazepoxide and hydroxyzine on psychomotor function and EEG.
Bartel, PR; Becker, PJ; Blom, MW; Sommers, DK; Van der Meyden, CH, 1992
)
0.52
" Repeated daily dosing with beta-CCE (up to 10 mg/kg) resulted in rapid tolerance to its rate-decreasing effects."( Effects of chlordiazepoxide and beta-carboline 3-carboxylic acid ethyl ester on non-suppressed and minimally-suppressed responding in the squirrel monkey.
Glowa, JR; Insel, TR, 1992
)
0.67
" Similarly, in pigeons trained to discriminate imipramine from saline, noneffective doses of CRF shifted the imipramine dose-response curve more than twofold to the left."( Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons.
Barrett, JE; Zhang, L, 1990
)
0.28
" These data support recent claims that GR38032F attenuates benzodiazepine withdrawal, and they indicate that this effect shows an inverted U-shaped dose-response curve."( Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats.
Goudie, AJ; Leathley, MJ, 1990
)
0.28
" Acute dosing of CDP (1-27 mg/kg) produced dose-related increases in basal CS secretion but was without effect on basal NA levels."( Effects of buspirone and chlordiazepoxide on plasma catecholamine and corticosterone levels in stressed and nonstressed rats.
De Boer, SF; Slangen, JL; Van der Gugten, J, 1991
)
0.58
" TRCP produced consistent signs of convulsive activity within 60-90 min after dosing and extensive loss of CAT hippocampal pyramidal cells when examined 7 days after dosing."( Acute exposure to tris(2-chloroethyl)phosphate produces hippocampal neuronal loss and impairs learning in rats.
Matthews, HB; McLamb, RL; Tilson, HA; Veronesi, B, 1990
)
0.28
" Chlordiazepoxide shifted the dose-response curves for TRH stimulation of PRL release and synthesis to the right, and did not change PRL release alone."( Pituitary thyrotropin-releasing hormone (TRH) receptors: effects of TRH, drugs mimicking TRH action, and chlordiazepoxide.
Hinkle, PM; Shanshala, ED, 1989
)
1.4
" The two drugs were administered four times a day in double dummy conditions, according to a fixed-flexible decreasing dosage schedule (six days basic regimen)."( Double blind study on the efficacy and safety of tetrabamate and chlordiazepoxide in the treatment of the acute alcohol withdrawal syndrome.
Chabot, F; Chawla, S; Forest, JC; Garcin, F; Guay, D; Huot, J; Marquis, PA; Martin, S; Radouco-Thomas, S; Stewart, G, 1989
)
0.51
" The dose-response curve produced by Ro 16-6028 was flatter than that for Ro 17-1812, however."( Further investigation of the stimulus properties of chlordiazepoxide and zolpidem. Agonism and antagonism by two novel benzodiazepines.
Sanger, DJ, 1987
)
0.52
" The dose-response curves for CCK8 were shifted in parallel to the right by 10(-6) to 10(-5) M of the three benzodiazepines, although the maximum response to CCK8 was depressed by higher concentrations."( Cholecystokinin antagonism by benzodiazepines in the contractile response of the isolated guinea-pig gallbladder.
Kubota, K; Matsuda, I; Sugaya, K; Sunagane, N; Uruno, T, 1985
)
0.27
" A flexible dosage schedule was followed for 5 days with the objective of using the largest dose on the first day, followed by daily reductions as clinically feasible."( Halazepam in the management of acute alcohol withdrawal syndrome.
Fine, EW; Mendels, J; Michals, TJ; Wasserman, TW, 1985
)
0.27
" Chlorpromazine caused a slight shift in the dose-response curves as did chlordiazepoxide when used with phencyclidine."( Quantitative electrocortical changes in the rat induced by phencyclidine and other stimulants.
Bond, A; Neal, H, 1985
)
0.5
" Dose-response curves for this effect are reported for chlordiazepoxide, diazepam and meprobamate."( Septal driving of hippocampal theta rhythm: role of gamma-aminobutyrate-benzodiazepine receptor complex in mediating effects of anxiolytics.
Gray, JA; McNaughton, N; Mellanby, J; Nordeen, H; Nutt, D; Quintero, S; Thompson, MR, 1985
)
0.52
" Dose-response studies revealed 13 (7."( A method for quantifying state-dependency with chlordiazepoxide in rats.
Colpaert, FC, 1986
)
0.53
" Lithium by itself in acute (2 meq kg-1, 24 and 4 h before test) or extended (2 meq kg-1 daily for 9 days) dosage had little effect on horizontal or vertical activity or levels of DA or DOPAC."( Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?
Aylmer, CG; Steinberg, H; Webster, RA, 1987
)
0.54
" Under conditions of such high aggression, the previously reported pro-aggressive action of a low (5 mg/kg) dosage of chlordiazepoxide (CDP) is hardly detectable."( Maternal aggression towards different sized male opponents: effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders.
Mos, J; Olivier, B; van Oorschot, R, 1987
)
0.72
" Furthermore, with increasing ethanol pretreatment the shift in dose-response curves for the loss-of-righting reflex was affected more than the shift in dose-response curves for lethality."( Ethanol drug interaction with chlordiazepoxide and pentobarbital.
Aaronson, LM; Okamoto, M; Rao, SN; Walewski, JL, 1985
)
0.56
" As dosage of these compounds increased, only small effects on accuracy were observed, followed at still larger doses by an abrupt and non-selective decrease in all responding."( Effects of pesticides and drugs on working memory in rats: continuous non-match.
Heise, GA; Hudson, JD, 1985
)
0.27
" Tolerance to ethanol or pentobarbital was characterized by a parallel shift of the dose-response curve to the right."( Tolerance to and cross-tolerance among ethanol, pentobarbital and chlordiazepoxide.
Grossi, F; Kalant, H; Khanna, JM; LĂȘ, AD, 1986
)
0.51
" After repetitive dosing with ketoconazole, chlordiazepoxide clearance decreased by 38% and was associated with reduced concentrations of its first oxidative metabolite, N-desmethylchlordiazepoxide."( Effect of ketoconazole on hepatic oxidative drug metabolism.
Brown, MW; Maldonado, AL; Meredith, CG; Speeg, KV, 1985
)
0.53
" The lack of a reciprocating effect of CDP-pretreatment was not likely to be due to the difference in initial dosage between ethanol and CDP."( Cross-tolerance between ethanol and chlordiazepoxide.
Aleo, MD; Chan, AW; Leong, FW; Schanley, DL,
)
0.41
" Analysis of dose-response curves suggested that CDZ is acting by a similar mechanism/site in both groups of rats but by a site different than ethanol."( Ethanol-chlordiazepoxide interactions in the rat.
Lovano, DM; Schechter, MD, 1985
)
0.7
" The GLC assay values (mean of 10 individual dosage units) for diazepam and flurazepam products were in good agreement with the results obtained by the pharmacopeial composite assays."( Routine quality evaluation of benzodiazepine drugs to USP-NF specifications.
Black, DB; Lawrence, RC; Lovering, EG; Watson, JR, 1981
)
0.26
" In order to further study the mechanism of brain stimulation punishment, dose-response curves of two minor tranquilizers, chlordiazepoxide and pentobarbital, of two tryptamine antagonists, methysergide and cyproheptadine as well as of amphetamine on lever-pressing behavior of rats maintained by water reinforcement and punished by DPAG stimulation were determined."( Effect of minor tranquilizers, tryptamine antagonists and amphetamine on behavior punished by brain stimulation.
de Aguiar, JC; Graeff, FG; Morato de Carvalho, S, 1981
)
0.47
"The elimination half-life of chlordiazepoxide and diazepam increases with age, and this may cause prolongation of action after a single dose and delayed accumulation on multiple dosing in elderly patients."( [Pharmacokinetic of benzodiazepines in old age].
Vozeh, S, 1981
)
0.55
"0 mg/kg) were examined in a subchronic (28 day) dosing regimen."( Acute and subchronic effects of neuroleptics on quantitative measures of discriminative motor control in rats.
Ford, KE; Fowler, SC; Gramling, SE; Nail, GL, 1984
)
0.27
" In animals implanted with chronically indwelling cannulae, a muscimol (25-400 ng) dose-response analysis confirmed the greater sensitivity of the MR site."( Intra-raphe muscimol induced hyperactivity depends on ascending serotonin projections.
Lorens, SA; Sainati, SM, 1982
)
0.26
" Pretreatment with the convulsant bemegride antagonized the pentobarbital transfer but not the chlordiazepoxide cue, whereas the specific benzodiazepine antagonist RO15-1788 decreased the chlordiazepoxide cue in a dose-response manner without attenuating the pentobarbital transfer."( Specific antagonism of the behavioral effects of chlordiazepoxide and pentobarbital in the rat.
Schechter, MD, 1984
)
0.74
"The pre- and postnatal effects of the combined oral administration of propoxyphene (PPX, 100 mg/kg/day) and chlordiazepoxide (CDX, 25, 50 or 100 mg/kg/day) were evaluated in Wistar rats in separate experiments by dosing on days 6 through 21 of pregnancy."( Pre- and postnatal development of rats following concomitant intrauterine exposure to propoxyphene and chlordiazepoxide.
Buttar, HS; Moffatt, JH,
)
0.56
" Based on the "chronically equivalent" dosing principle, a regimen has been devised to maintain rats in a state of quantifiable intoxication for 5 weeks."( Experimental induction of benzodiazepine tolerance and physical dependence.
Boisse, NR; Ryan, GP, 1983
)
0.27
" d-Amphetamine, cocaine, and caffeine each had the effect of elevating both bite and lever press responses; nicotine, chlorpromazine, chlordiazepoxide, and diazepam each elevated lever press responding while depressing bite responding across a portion of the dosage range; phenobarbital, alcohol, and morphine had the effect of depressing both bite and lever press responses but lever pressing was selectively more depressed than biting."( Unique influences of ten drugs upon post-shock biting attack and pre-shock manual responding.
Emley, GS; Hutchinson, RR, 1983
)
0.47
" Analyses of commercial dosage forms of chlordiazepoxide have shown the presence of demoxepam at concentrations in excess of the pharmacopoeial specifications in some aged samples."( Assay of chlordiazepoxide and demoxepam in chlordiazepoxide formulations by difference spectrophotometry.
Davidson, AG, 1984
)
0.95
" Improvement occurred after a single dose of the anxiolytic drugs but did not occur until 10-18 days after daily dosing with standard tricylic antidepressants and the MAO inhibitor isocarboxazid."( Effects of selected drugs on spontaneously occurring abnormal behavior in beagles.
Barnett, A; Brody, PE; Eisenstein, N; Iorio, LC, 1983
)
0.27
"Chromosomal preparations were examined for structural and numerical abnormalities induced by chlordiazepoxide (CDZ) in mice which received either a single oral dose (20 mg/kg) or multiple doses (10, 20, 40 and 80 mg/kg) for time-response and dose-response studies, respectively."( Cytogenetic effect of chlordiazepoxide on the bone marrow cells of Swiss mice in vivo.
Das, RK; Kar, RN, 1983
)
0.8
" Dose-response alteration of VI responding by apomorphine, d-amphetamine, clonidine, and chlordiazepoxide was studied along and in the presence of a dose of acrylamide which, by itself, did not alter VI responding."( The effects of acrylamide on the behavioral suppression produced by psychoactive agents.
Squibb, RE; Tilson, HA, 1982
)
0.49
" Graphic representation of the dose-response relationships suggested that these anxiolytics share a common site and/or mechanism of action that differs from that of ethanol."( Behavioral evidence for different mechanisms of action for ethanol and anxiolytics.
Schechter, MD, 1982
)
0.26
"Chlordiazepoxide HCl, a widely used tranquilizer, was evaluated for pre- and postnatal effects in rats by dosing orally on days 1--21 of gestation."( Effects of chlordiazepoxide on the pre- and postnatal development of rats.
Buttar, HS, 1980
)
2.09
" The method was used for the assay, content uniformity, and dissolution testing of dosage forms containing 5--30 mg of chlordiazepoxide and 12."( Simultaneous high-performance liquid chromatographic determination of chlordiazepoxide and amitriptyline hydrochloride in two-component tablet formulations.
Burke, D; Sokoloff, H, 1980
)
0.7
"A study was carried out in 80 mild to moderately depressed patients seen in general practice to assess the relative effectiveness and tolerance of a single night-time dose compared with the usual divided daily dosage regimen of a chlordiazepoxide (5 mg)/amitriptyline (12."( A comparison of a single night-time and a divided daily dosage regimen of a chlordiazepoxide/amitriptyline combination.
Dean, BC; James, RT, 1980
)
0.67
" The EC50 of the GABA dose-response curve for the alpha 1 beta 2 combination was lower than that for the alpha 1 beta 2 gamma 2s combination."( Alcohol modulation of cloned GABAA receptor-channel complex expressed in human kidney cell lines.
Carter, DB; Hamilton, BJ; Kurata, Y; Marszalec, W; Narahashi, T, 1993
)
0.29
" In Experiment 1, dose-response curves for the effects of the BZs chlordiazepoxide and diazepam, the barbiturates (BBs) pentobarbital and amobarbital, and the non-BZ, non-BB agent carbamazepine were determined in five groups of rats (one group/drug); dose-response curves were determined on two occasions for each drug."( Initial subsensitivity to anxiolytic treatments on conflict behavior in rats: parametric studies across drug classes.
Commissaris, RL; Hill, TJ; Kleinsorge, RJ; McMiller, LV,
)
0.37
" Tolerance was evaluated by constructing dose-response curves to CDP following chronic administration of either CDP or saline."( Differential regulation of the behavioral effects of chlordiazepoxide.
Lucki, I; Shumsky, JS, 1994
)
0.54
" We attempted to determine the length and type of hospital stay, and the pattern and appropriateness of administration, dosage requirements, and costs associated with benzodiazepines in patients undergoing alcohol withdrawal."( A retrospective review and assessment of benzodiazepines in the treatment of alcohol withdrawal in hospitalized patients.
Hoey, LL; Nahum, A; Vance-Bryan, K,
)
0.13
" In drug interaction test sessions caffeine (56 mg/kg) blocked the discriminative stimulus properties of the training dose of CDP and shifted the CDP discriminative dose-response function to the right."( Perceptual masking of the chlordiazepoxide discriminative cue by both caffeine and buspirone.
Gauvin, DV; Holloway, FA; Peirce, JM, 1994
)
0.59
" In new rats, a dose-response assessment revealed that 60 and 30 nmol, but not 10 nmol, CDP infused into the medial septum impaired spatial learning, but not cue learning or swim speed."( Effects of intracranial infusions of chlordiazepoxide on spatial learning in the Morris water maze. II. Neuropharmacological specificity.
McNamara, RK; Skelton, RW, 1993
)
0.56
" Finally, no significant differences were found between age groups in either the dosage or number of days of detoxification medication, although a trend was found for more days of medication in the elderly."( Severity and treatment of alcohol withdrawal in elderly versus younger patients.
Blow, FC; Brower, KJ; Hill, EM; Mudd, S; Young, JP, 1994
)
0.29
" Compared to behavior of vehicle-pretreated, room air-exposed rats, rat pairs exposed to nitrous oxide showed a generally inverted U-shaped dose-response curve with the maximum increase in social interaction encounters occurring at 25% and significant increase in time of active social interaction at 15-35%; higher concentrations produced a sedative effect that reduced social interaction."( Benzodiazepine receptor-mediated behavioral effects of nitrous oxide in the rat social interaction test.
Curtis, BA; Czech, DA; Hodges, BL; Maillefer, RH; Quock, RM; Wetzel, PJ, 1993
)
0.29
" Cumulative dose-response curves for chlordiazepoxide were obtained before and during chronic chlordiazepoxide administration and during chronic saline administration."( Tolerance to the behavioral effects of chlordiazepoxide: pharmacological and biochemical selectivity.
Alastra, AJ; Cohen, C; Goldberg, SR; Marley, RJ; Sannerud, CA; Serdikoff, SL, 1993
)
0.83
" Drug was most often given on a fixed dosing schedule with additional medication "as needed" (52% of the programs)."( Alcohol withdrawal: a nationwide survey of inpatient treatment practices.
Friedman, LS; Mayo-Smith, MF; Saitz, R, 1995
)
0.29
" Both the U-shaped dose-response curve seen with buspirone in some animal tests of anxiety and its slow onset of clinical action could be attributed to this release of stress hormones."( The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide.
Logan, B; McNaughton, N; Panickar, KS, 1996
)
0.52
"0 mg/kg) resulted in a dose-related parallel shift to the right in the dose-response function for PB-appropriate responding in all monkeys for all three BZs."( Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.
Nader, MA; Woolverton, WL, 1995
)
0.29
" Third, tolerance developed to the response-suppressant effects of CDP under the RI 80-s schedule, as indicated by a sixfold shift to the right in the dose-response curves for rats treated chronically with CDP when compared to saline-treated controls."( Differential tolerance to the effects of chlordiazepoxide on unpunished and punished operant responding following chronic treatment.
Lucki, I; Shumsky, JS, 1996
)
0.56
" The dissimilarity in dose-response curve of WAY-100635 on punished and unpunished behaviour poses questions about the mediation of these effects."( Effects of 5-HT1A receptor ligands in a modified Geller-Seifter conflict model in the rat.
Gommans, J; Hijzen, TH; Joordens, RJ; King, CM; Maes, RA; Olivier, B, 1997
)
0.3
" In test sessions preceded by doses of pentobarbital, chlordiazepoxide, or ethanol, pigeons switched from responding on the saline-biased key at low doses to responding on the pentobarbital-biased key at higher doses (the dose-response curve was quantal)."( Drug discrimination under a concurrent fixed-ratio fixed-ratio schedule.
Li, M; McMillan, DE, 1999
)
0.55
", necessity of an anxiogenic baseline, drug and receptor specificity, as well as the dose-response nature of the interaction, were discussed."( The inability of CCK to block (or CCK antagonists to substitute for) the stimulus effects of chlordiazepoxide.
Fox, MA; Levine, ES; Riley, AL,
)
0.35
" Under the FR schedule, pentobarbital dose-response curves were usually quantal, whereas under the FI schedule the pentobarbital dose-response curves usually were graded."( Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules.
Hardwick, WC; Li, M; McMillan, DE, 2001
)
0.31
" Thus, drug discrimination can be established under concurrent VR VR schedules, but the shapes of drug-discrimination dose-response curves under concurrent VR VR schedules more closely resemble those seen under interval schedules than those seen under fixed-ratio schedules."( Drug discrimination under concurrent variable-ratio variable-ratio schedules.
Hardwick, WC; Li, M; McMillan, DE, 2002
)
0.31
"Initial studies established a dose-response curve using different concentrations of Form, and also determined that avoidance of Form was abolished by pretreatment with an anxiolytic dose of chlordiazepoxide."( Repeated cocaine decreases the avoidance response to a novel aversive stimulus in rats.
Davidson, DL; Hochstatter, T; Sorg, BA; Sylvester, PW, 2002
)
0.5
" Usually, the slope of the dose-response lines for RWJ-51204 was more shallow than the full agonist anxiolytics but steeper than partial agonists in efficacy tests but typically shallow in tests for central nervous system side effects."( 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic.
Carter, AR; Cheo-Isaacs, CT; Crooke, JJ; DeLuca, S; DeVine, A; Dubinsky, B; Hochman, C; Jordan, AD; Reitz, AB; Rosenthal, DI; Shank, RP; Vaidya, AH, 2002
)
0.31
" In the second experiment, in order to assess the effects of chronic dosing or handling on baseline UEEPM behaviour, subjects received either 21 days vehicle injection (p."( Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide.
Duxon, MS; Jones, N; King, SM, 2002
)
0.51
" After responding stabilized, dose-response curves were determined for other drugs."( Retention of sequential drug discriminations under fixed-interval schedules for long time periods without training.
Li, M; McMillan, DE, 2003
)
0.32
" In order to investigate the relationship between tolerance and withdrawal to the cue properties of CDP, CDP dose-response curves were determined 24 h following treatment with SAL or 10 mg/kg CDP."( Evidence for PTZ-like cues as a function of time following treatment with chlordiazepoxide: implications for understanding tolerance and withdrawal.
Barrett, RJ; Smith, RL, 2005
)
0.56
" It has proven superior to the open field investigations in allowing dose-response effects to be observed over a relatively short observation period (i."( Development of a home cage locomotor tracking system capable of detecting the stimulant and sedative properties of drugs in rats.
Dunne, F; Kelly, JP; O'Halloran, A, 2007
)
0.34
" The pregnancy age-specific mean birth weight indicated intrauterine fetal growth retardation, which was confirmed by a dose-response relationship and by the higher rate of low birth-weight newborns."( A study of the teratogenic and fetotoxic effects of large doses of chlordiazepoxide used for self-poisoning by 35 pregnant women.
Acs, N; BĂĄnhidy, F; Czeizel, AE; Gidai, J,
)
0.37
"One hundred consecutive consenting male inpatients in a state of moderately severe, uncomplicated alcohol withdrawal at screening were randomized to receive either lorazepam (8 mg/day) or chlordiazepoxide (80 mg/day) with dosing down-titrated to zero in a fixed-dose schedule across 8 treatment days."( A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal.
Andrade, C; Kumar, CN; Murthy, P, 2009
)
0.79
" The products formed in marketed tablet dosage forms are similar to those formed during stress studies."( Stability-indicating HPLC method for simultaneous determination of clidinium bromide and chlordiazepoxide in combined dosage forms.
Pathak, A; Rai, P; Rajput, SJ, 2010
)
0.58
" Present findings therefore confirm the intrinsic anxiolytic activity of DCS in untrained animals, with the observed bell-shaped dose-response function most probably indicative of varying affinities and intrinsic activities at NMDA receptor subtypes."( Anxioselective profile of glycineB receptor partial agonist, D-cycloserine, in plus-maze-naĂŻve but not plus-maze-experienced mice.
Howard, K; Rodgers, RJ; Stewart, S; Waring, P; Wright, FL, 2010
)
0.36
" The validated HPLC methods were successfully applied to the analysis of their commercial tablet dosage forms, for which no interfering peaks were encountered from common pharmaceutical adjuvants."( Validated HPLC determination of the two fixed dose combinations (chlordiazepoxide hydrochloride and mebeverine hydrochloride; carvedilol and hydrochlorothiazide) in their tablets.
Belal, TS; Haggag, RS; Shaalan, RA,
)
0.37
" Renal dosing for topiramate, reduction in PIMs/anticholinergic burden, and substituting haloperidol for olanzapine resolved his violent behavior and CD."( Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.
Dawood, A; Kaufman, KR; Newman, NB, 2014
)
0.4
" The specificity of the developed methods was investigated by analyzing the laboratory mixtures and was successfully applied for their combined dosage form."( Simultaneous determination of mebeverine hydrochloride and chlordiazepoxide in their binary mixture using novel univariate spectrophotometric methods via different manipulation pathways.
Fayez, YM; Lotfy, HM; Michael, AM; Nessim, CK, 2016
)
0.68
" Once daily oral dosing of LY2940094 at 40 mg for 8 weeks vs placebo provided some evidence for an antidepressant effect based on the change from baseline to week 8 in the GRID-Hamilton Depression Rating Scale-17 item total score, although the predefined POC efficacy criterion (probability of LY2940094 being better than placeboâ©Ÿ88%) was not met (82."( A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Barth, V; Browning, M; Dawson, GR; Harmer, CJ; Jackson, K; Kakar, R; Krikke-Workel, J; McCarthy, A; Mohs, R; Post, A; Smart, TS; Statnick, M; Wafford, K; Witkin, JM, 2016
)
0.43
" This suggests that leptin behaves similarly to established serotonergic anxiolytics such as buspirone and fluoxetine; with the delay in development of effect during testing, and the inverted-U dose-response curve explaining the inconsistent behaviour of leptin in behavioural tests of anxiety, as this type of pattern is common to serotonergic anxiolytics."( Anxiolytic-like effects of leptin on fixed interval responding.
McNaughton, N; Munn, RG; Tyree, SM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency15.02250.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID743040
IDH1Homo sapiens (human)Potency7.30780.005210.865235.4813AID686970
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency10.00000.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency1.00000.004611.374133.4983AID624297
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)34.55000.11007.190310.0000AID1443980; AID1473738
Gamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)IC50 (µMol)0.99670.00050.53857.2000AID41996; AID41998
Gamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)IC50 (µMol)0.99670.00050.53857.2000AID41996; AID41998
Gamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)IC50 (µMol)0.99670.00050.53857.2000AID41996; AID41998
Gamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)IC50 (µMol)0.99670.00050.53857.2000AID41996; AID41998
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Ki0.63500.00000.21085.6234AID239699; AID72918; AID72919; AID72930
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Translocator proteinRattus norvegicus (Norway rat)Ki0.43800.00010.65108.9300AID39933
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)Ki0.48610.00000.18819.0000AID239699; AID239700; AID239701; AID239702; AID72918; AID72919; AID72930; AID73080; AID73081; AID73090; AID73235; AID73236; AID73245; AID73380; AID73382; AID73526
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.505710.0000AID40230; AID40519; AID40661
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)1.10000.00031.38338.4000AID41996
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.497310.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)IC50 (µMol)0.99670.00050.53857.2000AID41996; AID41998
Gamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)IC50 (µMol)0.99670.00050.53857.2000AID41996; AID41998
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.498810.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.504610.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)Ki0.48610.00010.20769.0000AID239699; AID239700; AID239701; AID239702; AID72918; AID72919; AID72930; AID73080; AID73081; AID73090; AID73235; AID73236; AID73245; AID73380; AID73382; AID73526
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)100.00000.00000.43624.3000AID52418
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00010.24801.4000AID52418
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Ki0.39400.00010.24425.6234AID239702; AID73380; AID73382; AID73526
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)Ki0.48920.00010.25155.6234AID239701; AID73235; AID73236; AID73245
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)1.79500.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.20800.00000.511010.0000AID625269
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)Ki0.42600.00010.24015.6234AID239700; AID73080; AID73081; AID73090
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.506510.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.505710.0000AID40230; AID40519; AID40661
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.21600.00010.507510.0000AID40230; AID40519; AID40661
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (194)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (54)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (278)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID72922Modulatory effect on coapplication with GABA at human Gamma-aminobutyric acid A receptor alpha-1-beta-3-gamma-2 in Xenopus oocyte.2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID1136299Anticonvulsant activity in po dosed mouse assessed as blockade of supramaximal electroshock-induced toxic seizure1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1144298Inhibition of nicotine-induced response in ip dosed CF-1 mouse1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Central nervous system depressants. 13. s-Triazolo-1,5-benzodiazepin-5-ones.
AID114042Muscle relaxation in mice by using Pull-Up test1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID352652Antitussive activity against capsaicin-induced cough in po dosed Hartley guinea pig model after 2 hrs2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID73090Displacement of [3H]Ro-151788 from human Gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 stably expressed in L(tk-) cells2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID1135581Anticonvulsant activity in po dosed CD-1 mouse assessed as protection against maximal electroshock-induced convulsion1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID131526Effective dose against tetrabenazine induced ptosis in mice administered orally1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID185195Minimum Effective Dose (MED) was measured using Food-Conflict test in rats1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID352653Anxiolytic activity in po dosed CD rats assessed as suppression of conditioned paw licking administered twice per day for 14 days measured after 2 hrs of last dose2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.
AID129024Anticonvulsant activity when bicuculline given subcutaneously in mouse1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
6-(Alkylamino)-3-aryl-1,2,4-triazolo[3,4-a]phthalazines. A new class of benzodiazepine receptor ligands.
AID168543The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (conflic) following dose of 20 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136301Acute toxicity in po dosed mouse assessed as mortality administered as qd for 6 days measured on day 7 post last dose1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1135134Acute toxicity in mouse measured following single ip dose1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID427371Anxiolytic-like activity in po dosed Dunkin-Hartley guinea pig assessed as reduction in number of separation-induced vocalizations after 2 hrs by guinea pig pup vocalization assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough.
AID40521Inhibitory concentration against specific binding of [3H]diazepam to Benzodiazepine receptor in rat brain1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Benzodiazepine receptor binding activity of 9-(1-phenylethyl)purines.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID139245Righting ability was determined in mice before rapid rolling (unaroused)1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID72919Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID243404In vitro percent efficacy against human gamma-aminobutyric-acid A receptor alpha-1-beta-3-gamma-2 expressed in L(tk-) cells2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID113267Anti-morphine activity against the morphine-induced Straub's tail reaction in mice on peroral administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID73227Percentage modulation of submaximal (EC20) response to GABA in Xenopus oocytes expressing human GABA-A alpha-3-beta-3-gamma-2 subunits2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID172736Percent change in Geller-Seifter conflict schedule was determined in Long-Evans rats after (po) administration of gavage of 25 mg/kg1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Benzodiazepine receptor binding activity of 8-substituted-9-(3-substituted-benzyl)-6-(dimethylamino)-9H-purines.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1135584Potentiation of hexobarbital-induced sedative effect in po dosed CD-1 mouse assessed as loss of righting reflex after 30 secs1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID1146382Antiacetylcholine activity in guinea pig ileum assessed as dose required to decrease 50 to 100% of acetylcholine-induced effect treated 5 mins before acetylcholine addition1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID76082Inhibition of binding of [125I]gastrin to guinea pig gastric glands1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID129287Antifighting potency against the foot shock induced fighting behavior in mice on peroral administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID114234Sedative/muscle relaxant effect in mice by using Rotating-Drum test1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID72910Percentage modulation of submaximal (EC20) response to GABA in Xenopus oocytes expressing human GABA-A alpha-1-beta-3-gamma-2 subunits2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1135583Anticonvulsant activity in po dosed CD-1 mouse assessed as protection against strychnine-induced convulsion after 30 mins1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID1136302Ratio of LD50 for po dosed mouse to PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID73512Percent of enzyme inhibition by Gamma-amino-N-butyrate transaminase assay method; ND means no data1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID1146384Antitrypatamine activity in isolated Wistar rat caudal artery assessed as dose required to decrease 20 to 50% of [3H]trypatamine-induced effect per 6 mL/min after 15 mins1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID352654Anxiolytic activity in Dunkin-Hartley guinea pig pup assessed as reduction in number of vocalization produced due to separation measured after 2 hrs2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID243405In vitro percent efficacy against human gamma-aminobutyric-acid A receptor alpha-2-beta-3-gamma-2 expressed in L(tk-) cells2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID193686Percent change in conflict responding in Long-Evans rats1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Benzodiazepine receptor binding activity of 9-(1-phenylethyl)purines.
AID1135129Antianxiety activity in ip dosed rat assessed as punished responding by conditioned lick suppression behavioral test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID259155Activity in rat elevated plus maze assay at 5 mg/kg, ip2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
AID185013Minimum effective dose (po) tested for its anxiolytic activity in rat using the shock-induced suppression of drinking (SSD) test.1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents.
AID1135582Anticonvulsant activity in po dosed CD-1 mouse assessed as protection against pentylenetetrazole-induced convulsion1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID72930Inhibition of [3H]Ro-151788 binding to human GABA A receptor (alpha-1-beta-3-gamma-2) stably expressed in L(tk-) cells.2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID168558The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (timeout) following dose of 20 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID52277Binding affinity towards cholecystokinin receptor by displacement of [125I]CCK-33 from guinea pig brain tissue1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID41996Inhibition of [3H]flunitrazepam binding to GABA-A central Benzodiazepine receptor of bovine brain membranes1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Specific inhibition of benzodiazepine receptor binding by some N-(indol-3-ylglyoxylyl)amino acid derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID128035Antagonism of pentylenetetrazole-induced convulsion in mice by oral administration.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel peptidoaminobenzophenones, terminal N-substituted peptidoaminobenzophenones, and N-(acylglycyl)aminobenzophenones as open-ring derivatives of benzodiazepines.
AID1135130Antianxiety activity in po dosed rat assessed as punished responding by conditioned lick suppression behavioral test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID1136286Antianxiety activity in ip dosed rat assessed as effect on increase in punished responses administered qd for 5 days measured every day for 5 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID168560The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (timeout) following dose of 5.0 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1144300Anticonvulsant activity in ip dosed CF-1 mouse assessed as reduction of pentylenetetrazole-induced response1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Central nervous system depressants. 13. s-Triazolo-1,5-benzodiazepin-5-ones.
AID168544The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (conflict) following dose of 0 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID353834Toxicity in rat assessed as total distance traveled at 30 mg/kg, po after 1 hr by spontaneous locomotor test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID134373Acute toxicity was measured in mice after peroral administration1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID139244Righting ability was determined in mice before rapid rolling (aroused)1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID168548The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (conflict) following dose of 5.0 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID73526Inhibition of [3H]Ro-151788 binding to human GABA A receptor (alpha-5-beta-3-gamma-2) stably expressed in L(tk-) cells.2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID352634Anxiolytic like activity in rat assessed as conditioned lick suppression after 2 hrs2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety.
AID184672Minimum effective dose on oral administration1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1135128Antipsychotic activity in ip dosed rat assessed as reduction in avoidance responding by Sidman avoidance test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID1144301Reduction in hypoxic stress in ip dosed CF-1 mouse1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Central nervous system depressants. 13. s-Triazolo-1,5-benzodiazepin-5-ones.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1146386Toxicity in albino mouse assessed as translatory movements at 10 mg/kg, ip relative to control1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID230747Ratio of the antifighting effect to muscle relaxant action1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID109527Antifighting activity was measured by the antagonism against foot-shock induced fighting1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Peptidoaminobenzophenones, a novel class of ring-opened derivatives of 1,4-benzoidazepines.
AID297274Anxiolytic activity in rat assessed as increase in social interaction time at 5 mg/kg, po relative to control2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists Part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit.
AID72918Inhibition of [3H]-Ro- 15-1788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-1-beta-3-gamma-22004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.
AID117077Lethal dose (LD50) required to inhibit the spontaneous motor activity.1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Peptidoaminobenzophenones, a novel class of ring-opened derivatives of 1,4-benzoidazepines.
AID353837Toxicity in rat assessed as time spent on rotarod at 3 mg/kg, po after 1 hr by rotarod test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID427372Anxiolytic-like activity in po dosed 20 hrs water-deprived CD rat after 2 hrs by conditioned lick suppression assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough.
AID134938Mouse behavior activity was determined; D = Depressant1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID113780Anticonvulsant activity in CD-1 mice with 120 mg/kg of leptazol1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1146385Toxicity in ip dosed mouse assessed as sedative action1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID129141Anticonvulsant activity when maximal electroshock is induced in mouse1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
6-(Alkylamino)-3-aryl-1,2,4-triazolo[3,4-a]phthalazines. A new class of benzodiazepine receptor ligands.
AID113693Inhibition of pentylenetetrazole (PTZ) induced convulsions in mice at 4 mg/kg after 30 min1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis, benzodiazepine receptor binding, and anticonvulsant activity of 2,3-dihydro-3-oxo-5H-pyrido[3,4-b][1,4]benzothiazine-4-carbonitriles.
AID73083Modulatory effect on coapplication with GABA at human Gamma-aminobutyric acid A receptor alpha-2-beta-3-gamma-2 expressed inXenopus oocytes2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID40839Binding constant was determined by displacing potential to [3H]-diazepam binding in cerebral cortex homogenates of rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID184854Minimum Effective Dose(MED was measured by using Licking-Conflict test in rats1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID73380Inhibition of [3H]-Ro- 15-1788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-5-beta-3-gamma-22004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.
AID129461Cataleptogenic action in mice on peroral administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID172224Effect on conflict responding in Long-Evans rats when 5 mg/kg was administered by oral gavage in a modified Geller-Seifter conflict schedule.1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Benzodiazepine receptor binding activity of 6,9-disubstituted purines.
AID129140Anticonvulsant activity when lethal dose of strychnine given subcutaneously in mouse1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
6-(Alkylamino)-3-aryl-1,2,4-triazolo[3,4-a]phthalazines. A new class of benzodiazepine receptor ligands.
AID134421Compound was evaluated for lethal dose in mouse in groups of ten (values in parentheses indicates 95% confidence limits)1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID353833Toxicity in rat assessed as total distance traveled at 10 mg/kg, po after 1 hr by spontaneous locomotor test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID41994Displacement of 3[H]Flunitrazepam from GABA-A central benzodiazepine receptor of bovine brain membranes1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID168556The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (timeout) following dose of 10 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136333Anxiolytic activity in po dosed rat assessed as protection against pentylenetetrazole-induced seizures administered in 2% starch1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Derivatives of 1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10H)-dione as anxiolytic agents.
AID1136339Toxicity in rat assessed as depression1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Derivatives of 1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10H)-dione as anxiolytic agents.
AID52418Binding affinity towards cholecystokinin receptor by the displacement of [125I]CCK-33 in rat pancreatic tissue1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.
AID40519Inhibition of specific binding of 1.5 nM [3H]diazepam to rat brain benzodiazepine receptors1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Benzodiazepine receptor binding activity of 8-substituted-9-(3-substituted-benzyl)-6-(dimethylamino)-9H-purines.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243406In vitro percent efficacy against human gamma-aminobutyric-acid A receptor alpha-3-beta-3-gamma-2 expressed in L(tk-) cells2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID1144299Anticonvulsant activity in ip dosed CF-1 mouse assessed as reduction of strychnine-induced response1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Central nervous system depressants. 13. s-Triazolo-1,5-benzodiazepin-5-ones.
AID1136303Therapeutic index, ratio of PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex to MED causing antianxiety activity in ip dosed rat assessed as effect on increase in punished responses1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID128166Activity was measured by rotarod test by intraperitoneal administration in mouse.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
6-(Alkylamino)-3-aryl-1,2,4-triazolo[3,4-a]phthalazines. A new class of benzodiazepine receptor ligands.
AID168552The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (reward) following dose of 20 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID73080Inhibition of [3H]-Ro- 15-1788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-2-beta-3-gamma-22004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.
AID210588Toxicity on peroral administration to mice1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID73073Percentage modulation of submaximal (EC20) response to GABA in Xenopus oocytes expressing human GABA-A alpha-2-beta-3-gamma-2 subunits2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID172097Effect on conflict responding in Long-Evans rats when 10 mg/kg was administered by oral gavage in a modified Geller-Seifter conflict schedule.1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Benzodiazepine receptor binding activity of 6,9-disubstituted purines.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID168549The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (reward) following dose of 0 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40835Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in rat cerebral cortex.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID353838Toxicity in rat assessed as time spent on rotarod at 10 mg/kg, po after 1 hr by rotarod test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID41998Inhibition of [3H]flunitrazepam binding to benzodiazepine receptor in bovine brain membrane1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ligands.
AID168545The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (conflict) following dose of 10 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID168561The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (timeout) following dose of 0 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID71452Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data)1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID73382Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-5-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID127859Compound was evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported, with the percent reversal at 10 mg/kg in parenthesis.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID193984Tested for situational anxiety in rats by measuring the latency exit from a chamber after po comparison with the activity values2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID132416Evaluated for muscle-relaxant action in mice on peroral administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID40230Concentration that inhibits binding of 1.5 nM [3H]diazepam to rat brain benzodiazepine receptor1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Benzodiazepine receptor binding activity of 6,9-disubstituted purines.
AID1148194CNS activity in po dosed mouse assessed as antagonism against pentylenetetrazole-induced response1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Quinazolines and 1,4-benzodiazepines. 81. s-Triazolo[4,3-a][1,4]benzodiazepines by oxidative cyclization of hydrazones.
AID1135133Acute toxicity in mouse measured following single po dose1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136287Muscle relaxant activity in po dosed mouse assessed as blockade of pentylenetetrazol-induced tonic extensor seizure1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID176408Evaluated for neuroleptic-like property using open-field test in rats(increase in ambulation at 3 to 20 mg/kg on peroral administration; Slight increase1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID239702Displacement of [3H]-Ro- 15-1788 from human gamma-aminobutyric-acid GABA-A receptor alpha-5-beta-3-gamma-2 expressed in L(tk-) cells 2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID39933Binding affinity against rat benzodiazepine (BZD) receptor2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists.
AID1135126Analgesic activity in po dosed mouse assessed as potentiation of ethanol-induced loss of the righting reflex in 50% mouse1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID114235Sedative/muscle relaxant effects in male CD-1 mice was assessed with a Ugo Basile rotating drum and the dose causing 50% decrease in time (ED50) was calculated.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors.
AID354393Toxicity in Sprague-Dawley rat assessed as total distance traveled at 30 mg/kg, po after 1 hr by open-field locomotor activity test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
AID112379The dose of leptazol-inducing tonic seizures in CD-1 mice was determined and represented as ED50.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors.
AID1460065Toxicity in water-deprived Sprague-Dawley rat assessed as effect on water drinking time during nonpunished period at 20 mg/kg, po by Vogel conflict test2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Synthesis and Characterization of a Novel Îł-Aminobutyric Acid Type A (GABA
AID111353Spontaneous motor activity of mice was estimated after 60 minutes of oral administration.1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Peptidoaminobenzophenones, a novel class of ring-opened derivatives of 1,4-benzoidazepines.
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID1136297Muscle relaxant activity in mouse assessed as blockade of pentylenetetrazol-induced tonic extensor seizure at 40 mg/kg, po1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID40661In vitro for inhibition of [3H]diazepam towards Benzodiazepine receptor from rat1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID353832Toxicity in rat assessed as total distance traveled at 3 mg/kg, po after 1 hr by spontaneous locomotor test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID1146383Antinoradrenaline activity in isolated Wistar rat caudal artery assessed as dose required to decrease 20 to 50% of noradrenaline-induced effect per 6 mL/min after 15 mins1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136298Muscle relaxant activity in po dosed mouse assessed as increase in strychnine-induced persistant convulsive threshold1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1135585Potentiation of chlorprothixene-induced sedative effect in po dosed CD-1 mouse assessed as loss of righting reflex1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID239700Displacement of [3H]-Ro- 15-1788 from human gamma-aminobutyric-acid GABA-A receptor alpha-2-beta-3-gamma-2 expressed in L(tk-) cells 2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID134240Acute toxicity expressed as LD50 in mice after oral administration.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel peptidoaminobenzophenones, terminal N-substituted peptidoaminobenzophenones, and N-(acylglycyl)aminobenzophenones as open-ring derivatives of benzodiazepines.
AID168554The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (reward) following dose of 5.0 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID114833Effective dose required for 50% reduction of the control response was obtained by graphical interpolation rotarod performance1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Peptidoaminobenzophenones, a novel class of ring-opened derivatives of 1,4-benzoidazepines.
AID128039Anticonvulsant activity against pentylenetetrazole-induced clonic seizures in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID73235Inhibition of [3H]-Ro- 15-1788 binding to recombinant human gamma-aminobutyric-acid A receptor alpha-3-beta-3-gamma-22004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.
AID1135580Antianxiety activity in po dosed CD-1 mouse assessed as inhibition of foot shock-induced aggression after 30 mins relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID115612Minimum effective dose (MED) required for the potentiation of thiopental sodium induced loss of the righting reflex (Students t test).1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Peptidoaminobenzophenones, a novel class of ring-opened derivatives of 1,4-benzoidazepines.
AID73245Binding affinity by displacement of [3H]Ro-151788 from recombinant human gamma-aminobutyric-acid A receptor alpha3,beta3,gamma2 stably expressed in L cells2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID1135127Analgesic activity in po dosed mouse assessed as potentiation of sodium barbital-induced loss of the righting reflex in 50% mouse1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.
AID73081Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-2-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID177059In vivo protection against pentylenetetrazole-induced convulsions in the rat.1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID74657Percent of enzyme inhibition by Glutamate decarboxylase assay method; ND means no data1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID73373Percentage modulation of submaximal (EC20) response to GABA-A receptor alpha-5-beta-3-gamma-2 subunits expressed in mouse fibroblast L(tk-) cells2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.
AID40663In vitro inhibition of [3H]diazepam binding towards Benzodiazepine receptor at 1 uM1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID239699Displacement of [3H]-Ro- 15-1788 from human gamma-aminobutyric-acid GABA-A receptor alpha-1-beta-3-gamma-2 expressed in L(tk-) cells 2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID73237Modulatory effect on coapplication with GABA at human Gamma-aminobutyric acid A receptor alpha-3-beta-3-gamma-2 in Xenopus oocytes.2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID1146375Acute toxicity in ip dosed albino mouse measured within 24 hrs1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID172099Effect on conflict responding in Long-Evans rats when 25 mg/kg was administered by oral gavage in a modified Geller-Seifter conflict schedule.1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Benzodiazepine receptor binding activity of 6,9-disubstituted purines.
AID353835Toxicity in rat assessed as total distance traveled at 100 mg/kg, po after 1 hr by spontaneous locomotor test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID1148193CNS activity in po dosed mouse assessed as antifighting activity by foot shock test1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Quinazolines and 1,4-benzodiazepines. 81. s-Triazolo[4,3-a][1,4]benzodiazepines by oxidative cyclization of hydrazones.
AID131235Muscle relaxation activity using the rotarod performance test in mice by oral administration.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel peptidoaminobenzophenones, terminal N-substituted peptidoaminobenzophenones, and N-(acylglycyl)aminobenzophenones as open-ring derivatives of benzodiazepines.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1146381Antihistamine activity in guinea pig ileum assessed as dose required to decrease 50 to 100% of histamine induced effect treated 5 mins before histamine addition1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID177859Effective dose against pentylenetetrazole intoxicity in mice administered orally1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID40227Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat cerebral cortex membrane1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1136290Blockade of pentylenetetrazol-induced lethality in mouse at 40 mg/kg, po1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID353839Toxicity in rat assessed as time spent on rotarod at 30 mg/kg, po after 1 hr by rotarod test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID11307291-Octanol-aqueous phosphate buffer partition coefficient, log P of the compound at pH 7.351979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID40836Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1146387Anticonvulsant activity in ip dosed albino mouse assessed as dose causing total prevention of maximal electroshock-induced maximal extensor seizure1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136300Acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex administered as qd for 4 days measured for 1 min post last dose1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Pyrrolidinylideneureas, a new class of central nervous system agents.
AID40833Inhibition of binding of tritiated 3[H]diazepam radioligand to rat brain homogenates1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis, benzodiazepine receptor binding, and anticonvulsant activity of 2,3-dihydro-3-oxo-5H-pyrido[3,4-b][1,4]benzothiazine-4-carbonitriles.
AID140702Evaluated for hypothermic activity in mice at 30 mg/kg on peroral administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1148192CNS activity in po dosed mouse by inclined screen test1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Quinazolines and 1,4-benzodiazepines. 81. s-Triazolo[4,3-a][1,4]benzodiazepines by oxidative cyclization of hydrazones.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID113320Dose required to prevent convulsion and death in 50% of mice during a 2 hr observation was obtained by graphical interpolation anti-pentylenetetrazole1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Peptidoaminobenzophenones, a novel class of ring-opened derivatives of 1,4-benzoidazepines.
AID177740Activity was measured by rotarod test by peroral administration in rat1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
6-(Alkylamino)-3-aryl-1,2,4-triazolo[3,4-a]phthalazines. A new class of benzodiazepine receptor ligands.
AID1135586Induction of muscle relaxation in po dosed CD-1 mouse after 30 mins by rotary drum test1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID354394Toxicity in Sprague-Dawley rat assessed as time spent on rotarod at 30 mg/kg, po after 1 hr by rotarod test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1146376Neurotoxicity in albino mouse at 10 mg/kg, po up to 5 mins by rotorod test relative to control1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
AID73374Percentage modulation of submaximal (EC20) response to GABA in Xenopus oocytes expressing human GABA-A alpha-5-beta-3-gamma-2 subunits2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID73372Percentage modulation of submaximal (EC20) response to GABA-A receptor alpha-5-beta-3-gamma-2 subunits expressed in Xenopus laevis oocytes2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.
AID73236Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-3-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID243407In vitro percent efficacy against human gamma-aminobutyric-acid A receptor alpha-5-beta-3-gamma-2 expressed in L(tk-) cells2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID239701Displacement of [3H]-Ro- 15-1788 from human gamma-aminobutyric-acid GABA-A receptor alpha-3-beta-3-gamma-2 expressed in L(tk-) cells 2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
AID40231Inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of rat cerebral cortex1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents.
AID168550The compound was evaluated for the anticonflict behavior in male wistar rats as rate of responses (reward) following dose of 10 mg/kg po1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
AID1135587Acute toxicity in po dosed CD-1 mouse assessed as mortality after 24 hrs1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Central nervous system activity of a novel class of annelated 1,4-benzodiazepines, aminomethylene-2,4-dihydro-1H-imidazo[1,2-a][1,4]benzodiazepin-1-ones.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID176404Evaluated for neuroleptic-like property using anti-methamphetamine test in rats on peroral administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Synthesis and antianxiety activity of (omega-piperazinylalkoxy)indan derivatives.
AID132137Compound was evaluated for antagonism of reserpine induced hypothermia;I= Inactive.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID493017Wombat Data for BeliefDocking2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346296Rat TRH1 receptor (Thyrotropin-releasing hormone receptors)1989Annals of the New York Academy of Sciences, , Volume: 553Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.
AID1346370Mouse TRH1 receptor (Thyrotropin-releasing hormone receptors)1990Proceedings of the National Academy of Sciences of the United States of America, Dec, Volume: 87, Issue:24
Expression cloning of a cDNA encoding the mouse pituitary thyrotropin-releasing hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,669)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902921 (79.61)18.7374
1990's397 (10.82)18.2507
2000's221 (6.02)29.6817
2010's116 (3.16)24.3611
2020's14 (0.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.96 (24.57)
Research Supply Index8.38 (2.92)
Research Growth Index4.10 (4.65)
Search Engine Demand Index189.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (100.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials385 (9.72%)5.53%
Reviews132 (3.33%)6.00%
Case Studies88 (2.22%)4.05%
Observational0 (0.00%)0.25%
Other3,357 (84.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder [NCT01109030]Phase 2/Phase 350 participants (Actual)Interventional2010-04-30Completed
A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study [NCT00516854]100 participants (Anticipated)Interventional2002-06-30Recruiting
Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients [NCT00136617]Phase 3165 participants (Actual)Interventional2003-08-31Completed
A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome [NCT03012815]Phase 488 participants (Actual)Interventional2017-02-01Completed
Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment [NCT01573052]Phase 426 participants (Actual)Interventional2004-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01573052 (3) [back to overview]Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)
NCT01573052 (3) [back to overview]Epworth Sleepiness Scale (ESS)
NCT01573052 (3) [back to overview]PENN Alcohol Craving Scale
NCT03012815 (8) [back to overview]Change in Anxiety Symptoms as Measured by the Generalized Anxiety Disorder-7 (GAD-7) Scale
NCT03012815 (8) [back to overview]Change in Cravings as Assessed by the Penn Alcohol Craving (PACS) Scale
NCT03012815 (8) [back to overview]Change in Sleepiness as Assessed by the Epworth Sleepiness Scale
NCT03012815 (8) [back to overview]Maximun Alcohol Withdrawal Severity Per CIWA-Ar Scale
NCT03012815 (8) [back to overview]Mean Length of Hospital Stay
NCT03012815 (8) [back to overview]Mean Total Benzodiazepine Use
NCT03012815 (8) [back to overview]Number of Participants Experiencing Seizure
NCT03012815 (8) [back to overview]Number of Participants With Delirium Tremens (DT)

Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)

CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Many previously publications suggest a total score of 8-10 is severe enough to warrant medication treatment. Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT01573052)
Timeframe: 1 week

Interventionunits on a scale (Mean)
Chlordiazepoxide3.29
Gabapentin4.33

[back to top]

Epworth Sleepiness Scale (ESS)

ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness. (NCT01573052)
Timeframe: 1 week

Interventionunits on a scale (Mean)
Chlordiazepoxide6.35
Gabapentin2.65

[back to top]

PENN Alcohol Craving Scale

PENN is a 5 item self-rated scale of alcohol craving. Scores range from 0 (little craving for alcohol) to 30 (irresistable urge to drink alcohol) (NCT01573052)
Timeframe: 1 week

Interventionunits on a scale (Mean)
Chlordiazepoxide16.78
Gabapentin10.74

[back to top]

Change in Anxiety Symptoms as Measured by the Generalized Anxiety Disorder-7 (GAD-7) Scale

GAD-7 is GAD-7 is a 7-item self-administered scale of Generalized Anxiety Disorder symptoms (0 = not at all to 3 = nearly every day). Total scores range from 0 to 21. Total scores of 0-4 = minimal anxiety, Total scores of 5-9 = mild anxiety, total scores of 10-14 = moderate anxiety and total scores of 15-21 = severe anxiety. (NCT03012815)
Timeframe: Baseline and 2 days

Interventionscore on a scale (Mean)
Gabapentin-0.07
Benzodiazepine-3.79

[back to top]

Change in Cravings as Assessed by the Penn Alcohol Craving (PACS) Scale

PACS is a 5 item self-rated scale of alcohol craving (0 = none to 6 = strong urge). Total scores range from 0 (little craving for alcohol) to 30 (irresistible urge to drink alcohol) (NCT03012815)
Timeframe: Baseline and 2 days

Interventionscore on a scale (Mean)
Gabapentin-8.12
Benzodiazepine-8.45

[back to top]

Change in Sleepiness as Assessed by the Epworth Sleepiness Scale

The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their daytime sleepiness. (NCT03012815)
Timeframe: Baseline and 2 days

Interventionscore on a scale (Mean)
Gabapentin-0.03
Benzodiazepine0.07

[back to top]

Maximun Alcohol Withdrawal Severity Per CIWA-Ar Scale

CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: 4 days

Interventionscore on a scale (Mean)
Gabapentin13.15
Benzodiazepine12.81

[back to top]

Mean Length of Hospital Stay

The length of hospital stay for Alcohol withdrawal syndrome. The time interval between admission and either discharge or the time at which Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar) scores are <10 for 36 hours (up to 240 hours). Measured in hours. CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.

Interventionhours (Mean)
Gabapentin44.91
Benzodiazepine50.50

[back to top]

Mean Total Benzodiazepine Use

The total amount of benzodiazepines administered. Measured by lorazepam equivalent, mg. (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.

Interventionmilligrams (Mean)
Gabapentin5.2
Benzodiazepine10.8

[back to top]

Number of Participants Experiencing Seizure

The number of subjects who developed seizure during their hospitalization. (NCT03012815)
Timeframe: During hospitalization (up to 240 hours).

InterventionParticipants (Count of Participants)
Gabapentin0
Benzodiazepine0

[back to top]

Number of Participants With Delirium Tremens (DT)

The number of participants experiencing delirium tremens during their hospitalization (between admission and discharge). (NCT03012815)
Timeframe: During hospitalization (up to 240 hours)

InterventionParticipants (Count of Participants)
Gabapentin0
Benzodiazepine0

[back to top]